Is CJC-1295 Legal in Arizona? How to Access It Legally

What Is CJC-1295 and Why Does Its Legal Status Matter?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds GHRH receptors in the pituitary gland, stimulating the release of endogenous growth hormone in a pulsatile pattern that more closely mirrors normal physiology than exogenous recombinant human growth hormone (rhGH) injections. Two versions circulate clinically: CJC-1295 without DAC (drug affinity complex), which has a half-life of roughly 30 minutes, and CJC-1295 with DAC, which extends the half-life to approximately 6 to 8 days through covalent albumin binding [1].

Because growth hormone secretagogues can affect body composition, recovery, sleep architecture, and insulin-like growth factor 1 (IGF-1) levels, demand among patients pursuing anti-aging, athletic recovery, and GH-deficiency management has grown sharply. That demand runs directly into federal and state regulatory frameworks that have tightened considerably since 2020.

Why Legal Status Is Not Simple

No state, including Arizona, has the authority to independently approve a drug for human use. Drug approval is exclusively a federal function of the FDA under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Arizona's contribution is regulating pharmacies that compound, dispense, and distribute substances within state lines, and licensing the prescribers who order them [2].

CJC-1295 has never completed an FDA New Drug Application (NDA) process. That single fact places it in a gray zone where its legality for human use depends entirely on whether the compounding pathway being used complies with the FD&C Act as amended by the Drug Quality and Security Act (DQSA) of 2013.

The DAC vs. No-DAC Distinction in Practice

From a regulatory standpoint, both CJC-1295 formulations share the same federal status: neither is an FDA-approved drug. In practice, prescribers and compounders treat them as distinct formulations requiring separate prescriptions. A prescription for "CJC-1295 with DAC 2 mg/mL injectable" is not interchangeable with a "CJC-1295 without DAC 1 mg/mL" order.

Federal Framework: The FDA's Position on CJC-1295

Understanding Arizona's rules requires understanding federal law first, because Arizona pharmacy law explicitly incorporates FDA compounding standards.

The 503A vs. 503B Distinction

The DQSA created two separate compounding categories under the FD&C Act [3]:

• 503A pharmacies are traditional compounding pharmacies that fill individual patient prescriptions on a small scale. They are exempt from FDA's Current Good Manufacturing Practice (cGMP) requirements but must not compound drug substances on the FDA's "Category 2" bulk substances list (substances the FDA has determined are not appropriate for compounding).
• 503B outsourcing facilities voluntarily register with the FDA, operate under cGMP, and may compound larger quantities for health-system use. They are governed by a separate bulk substances list and face stricter oversight.

CJC-1295 on the FDA Bulk Substances List

This is the regulatory crux for Arizona patients. In 2023, the FDA finalized its evaluation of numerous bulk drug substances nominated for 503A compounding. CJC-1295 (both with and without DAC) was placed in Category 2, meaning it may NOT be compounded by 503A pharmacies for individual patient prescriptions [4].

The FDA's reasoning, published in the Federal Register, cited the absence of clinical evidence establishing that the compounded substance presents a clinical difference from available FDA-approved alternatives (specifically, approved rhGH products such as somatropin). The agency noted that nominating parties did not submit adequate clinical data to support 503A inclusion.

For 503B outsourcing facilities, a separate bulk substances list applies. As of January 2025, CJC-1295 does not appear on the FDA's affirmative 503B bulk substances list either, placing 503B compounding in a similarly uncertain position [4].

What "Research Use Only" Actually Means

Chemical suppliers routinely sell CJC-1295 labeled "For Research Use Only" (RUO). Purchasing RUO peptides for personal self-injection is not a legal gray area. It is a clear violation of the FD&C Act, because introducing an unapproved drug into interstate commerce for human use is prohibited regardless of labeling [5]. The RUO label does not create a legal carve-out for individuals. It signals that the manufacturer has not validated the product for human safety or efficacy, and that the FDA does not oversee its purity, potency, or sterility.

Arizona State Law: What the State Pharmacy Board Says

Arizona Pharmacy Practice Act

Arizona Revised Statutes (A.R.S.) Title 32, Chapter 18 governs pharmacy practice in the state. The Arizona State Board of Pharmacy (AZBOP) licenses pharmacies and pharmacists and enforces compounding standards that, for sterile preparations, align with United States Pharmacopeia (USP) Chapter 797 requirements and federal law [6].

A licensed 503A pharmacy in Arizona may NOT compound CJC-1295 for patient use because federal law (which Arizona incorporates by reference for compounding standards) prohibits it under the Category 2 designation. Any Arizona retail compounding pharmacy currently dispensing CJC-1295 to patients is operating outside federal law, regardless of state licensure status.

What Arizona Prescribers Can and Cannot Do

A licensed Arizona prescriber (MD, DO, NP with full prescriptive authority, or PA under collaborative agreement) may write a prescription for CJC-1295. Writing the prescription itself is within their scope of practice under A.R.S. 32-1401 and related statutes governing medical practice. The problem arises at the dispensing step: a compliant 503A pharmacy cannot fill it, and a 503B facility can only compound CJC-1295 if it appears on the appropriate federal bulk substances list, which it currently does not [4].

This creates a practical gap between a legal prescription and a legal supply chain.

Arizona Medical Practice Act and Off-Label Use

Arizona's medical practice act does not prohibit off-label prescribing. Prescribers have broad latitude to prescribe FDA-approved drugs for unapproved indications based on clinical judgment. CJC-1295, however, is not an FDA-approved drug in any form. Off-label prescribing applies to approved drugs used outside their labeled indication, not to unapproved substances [7]. That distinction matters enormously for both the prescriber's liability exposure and the patient's legal standing.

How Patients in Arizona Are Currently Accessing CJC-1295

The following framework summarizes the four access paths Arizona patients attempt, with a legal assessment of each.

Path 1: Licensed 503A Compounding Pharmacy (Currently Non-Compliant)

Some Arizona-licensed 503A pharmacies continue to compound and dispense CJC-1295 despite the Category 2 listing. Patients who obtain it this way may not be aware of the regulatory violation occurring at the pharmacy level. The FDA has issued warning letters to compounders dispensing Category 2 substances, and enforcement actions have increased since 2022 [5]. This path carries risk for the pharmacy and creates uncertainty about product quality for the patient.

Path 2: 503B Outsourcing Facility with Physician Oversight

A small number of 503B facilities operate in a legal gray area by arguing that their bulk substance lists differ from 503A lists. The FDA has not finalized a definitive 503B-specific prohibition on CJC-1295 compounding as of this writing, though the agency's general position is that unapproved substances without adequate safety and efficacy data should not be compounded. Patients who access CJC-1295 through a physician-supervised 503B supply chain are in a less clearly prohibited position than 503A patients, but this is not a clean legal pathway [4].

Path 3: FDA-Approved GHRH Analog (Tesamorelin)

Tesamorelin (Egrifta SV) is an FDA-approved GHRH analog indicated for HIV-associated lipodystrophy. It works through the same receptor mechanism as CJC-1295, stimulating pulsatile GH release. Prescribers may not legally prescribe it off-label for body composition or anti-aging in the general population without significant liability exposure, but for patients with documented GH deficiency or HIV-related indications, it represents a fully legal, FDA-regulated option [8]. A randomized controlled trial published in JAMA (N=412) found tesamorelin reduced visceral adipose tissue by 18% versus placebo at 26 weeks (P<0.001) [8].

Path 4: Telehealth Prescribers and Out-of-State Pharmacies

Some telehealth platforms prescribe CJC-1295 and connect patients with compounding pharmacies in other states. Arizona law requires that a prescriber hold an Arizona license to prescribe to an Arizona patient, and that any pharmacy shipping controlled or regulated substances into Arizona hold an Arizona non-resident pharmacy permit from AZBOP [6]. Even with compliant licensure on both ends, the federal prohibition on 503A compounding of Category 2 substances does not change based on state of origin.

Clinical Evidence: What the Research Actually Shows for CJC-1295

Legal complexity aside, patients and prescribers deserve an honest summary of the available human evidence.

GH and IGF-1 Elevation

A Phase I/II dose-escalation trial published in the Journal of Clinical Endocrinology and Metabolism (JCEM) tested CJC-1295 with DAC in 66 healthy adults aged 21 to 61. Single doses of 30 to 120 mcg/kg produced dose-dependent increases in mean GH levels of 2-fold to 10-fold above baseline within 2 hours, with IGF-1 levels elevated for 6 to 14 days after a single injection [9]. These pharmacodynamic findings are clinically meaningful but the trial was not powered to assess body composition outcomes, adverse event rates at scale, or long-term safety.

What Is Still Unknown

No randomized controlled trial has examined CJC-1295 specifically for muscle mass, fat loss, or recovery in healthy adults over 12 or more weeks with adequate power. The FDA's concern, reflected in its Category 2 designation, is precisely this evidence gap. Growth hormone secretagogues as a class have shown modest body composition effects in GH-deficient populations. A Cochrane review of GH therapy in adults with GH deficiency (N=422 across 10 trials) found increases in lean body mass averaging 1.6 kg and reductions in fat mass averaging 1.6 kg, but also noted increased rates of fluid retention, joint pain, and glucose intolerance [10].

IGF-1 and Cancer Risk

Chronic supraphysiologic IGF-1 elevation is associated with increased colorectal, breast, and prostate cancer risk in epidemiologic data [11]. This does not mean that physiologic GH stimulation via GHRH analogs causes cancer. But it is a safety consideration that any prescribing physician must address before initiating therapy, and it is part of why the FDA has not embraced unregulated compounding of GHRH analogs.

What Legitimate Access Actually Requires in Arizona

A medically defensible, legally defensible path to CJC-1295 in Arizona (to the degree one exists given the 503A prohibition) requires all of the following:

Step 1: Establish Care with a Licensed Arizona Prescriber

The prescriber must hold an active Arizona medical, osteopathic, nurse practitioner, or physician assistant license. A telehealth visit satisfies this requirement if the platform complies with Arizona telehealth practice standards under A.R.S. 36-3601 et seq. The prescriber must take a full medical history, review labs (at minimum: IGF-1, fasting glucose, HbA1c, lipid panel, and baseline body composition or DXA), and document clinical justification for the prescription.

Step 2: Lab-Based Candidacy Assessment

No responsible prescriber should initiate a GHRH analog without baseline labs. IGF-1 reference ranges vary by age and sex. The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults specifies that biochemical confirmation of GHD requires either a GH stimulation test result or, in patients with three or more pituitary hormone deficiencies, a low IGF-1 combined with clinical history [12]. Patients with normal IGF-1 seeking CJC-1295 for performance purposes do not meet GHD diagnostic criteria.

Step 3: Pharmacy Verification

Ask the dispensing pharmacy directly whether it is a 503A or 503B facility, whether it is licensed by the Arizona State Board of Pharmacy (or holds a non-resident permit), and whether it is aware of the FDA's Category 2 designation for CJC-1295. A pharmacy that cannot answer these questions clearly should not be trusted with sterile injectable compounding.

Guideline Statements and Expert Positions

The Endocrine Society's position statement on GHRH analogs and GH secretagogues states that "use of growth hormone-releasing peptides and secretagogues outside of approved clinical trials or established GH deficiency indications is not supported by sufficient evidence to recommend in clinical practice" [12].

The American Association of Clinical Endocrinology (AACE) similarly cautions against routine use of GH secretagogues for anti-aging or body composition optimization in the absence of documented GHD, citing the IGF-1 cancer risk signal and lack of long-term safety data [13].

These positions do not make CJC-1295 therapy unethical or clinically unjustifiable in every case. They do mean that a physician prescribing it for a healthy 35-year-old who wants to lose body fat is operating well outside guideline support and assumes significant medicolegal exposure.

Penalties for Non-Compliant Access

Individuals who purchase CJC-1295 from RUO suppliers for self-injection are not typically the FDA's enforcement target. The agency focuses on manufacturers, distributors, and compounders who violate the FD&C Act. Arizona state law does not independently criminalize possession of an unapproved peptide for personal use in the way that Schedule II or III controlled substances are criminalized.

The practical risks for patients are product quality and safety, not criminal prosecution. RUO peptides are not subject to sterility testing, endotoxin testing, or potency verification. A 2022 analysis by the FDA of seized compounded injectable products found that 19 of 50 samples failed one or more quality tests, including sterility failures in 8 samples [5]. Injecting a non-sterile preparation carries real risk of abscess, septicemia, and endocarditis.

Monitoring if You Are Prescribed CJC-1295

For patients who do obtain CJC-1295 through a physician-supervised pathway, monitoring should occur at baseline, 8 weeks, and 16 weeks and should include:

• Serum IGF-1 (target: mid-normal for age and sex, not supraphysiologic)
• Fasting glucose and HbA1c (GH is diabetogenic at elevated levels)
• Lipid panel
• Blood pressure
• Symptom review for fluid retention, carpal tunnel symptoms, and joint pain

The Endocrine Society recommends keeping IGF-1 within the age-adjusted reference range during any GH-axis stimulation therapy to minimize long-term risk [12].